Académique Documents
Professionnel Documents
Culture Documents
OCT. 2015
W
W
W
.
C
A
P
I
T
A
L
S
T
A
R
S
.
C
O
M
MARKET SNAPSHOT
SYMBOL
OPEN
HIGH
LOW
CLOSE
CHANGE
NIFTY
8231
8244
8128
8189
-0.56%
SENSEX
27242
27305
26855
26904
-0.65%
Nifty levels:
Nifty spot close @8189
Nifty future close @8154
SYMBOL
NIFTY SPOT
NIFTY
FUTURE
S1
8099
8111
S2
8055
8068
PIVOT
8171
8179
R1
8215
8222
R2
8287
8290
Consolidation from upper level we have seen today, though buying opportunity on every
dip. We may see 8225 level as a next resistance level, more buying will be seen from this
level.
SYMBOL
BANKNIFTY
SPOT
BANKNIFTY
FUTURE
S1
S2
PIVOT
R1
R2
17497
17411
17628
17714
17845
17496
17391
17655
17760
17919
View on Banknifty
Selling opportunity below 17700, we may see 17400/17350 level, above 177700 we may
see 17850 as a strong resistance level.
Market Commentary
MARKET COMMENTERY
IT major and index heavyweight Infosys led losses for key benchmark indices, with the
stock sliding after the company cut full year revenue growth guidance in dollar terms. The
barometer index, the S&P BSE Sensex, fell 167.35 points or 0.62% at 26,912.16, as per the
provisional closing data. The 50-unit CNX Nifty dropped 46.10 points or 0.56% at 8,143.60,
as per the provisional closing data. The Sensex provisionally settled below the
psychological 27,000 level after falling below that mark in mid-afternoon trade.
STOCK BUZZ
Shares of IT major Infosys edged lower in choppy trade after the company
lowered its full year revenue growth guidance in dollar terms for the year
ending 31 March 2016 (FY 2016) at the time of announcement of Q2
September 2015 results. The stock was off 3.93% at Rs 1,122. The stock hit a
high of Rs 1,219 in intraday trade, which is a record high for the counter. The
stock hit a low of Rs 1,108.90 in intraday trade. Infosys now expects its
revenue to grow 6.4%-8.4% in dollar terms for FY 2016. At the time of
announcing Q1 June 2015 results, Infosys had forecast revenue growth of
7.2%-9.2% in dollar terms for FY 2016.
Pharma stocks were mostly lower. Lupin (down 2.01%), Sun Pharmaceutical
Industries (down 1.32%), Dr Reddy's Laboratories (down 1.59%), Cipla (down
1.55%), Ipca Laboratories (down 0.07%) and Strides Arcolab (down 0.1%)
edged lower. GlaxoSmithkline Pharmaceuticals (up 0.2%), Glenmark
Pharmaceuticals (up 2.23%), Divi's Laboratories (up 0.12%) and Wockhardt (up
0.35%) edged higher.
HOT PURSUIT
Bank of Baroda (BoB) tumbled 3.29% at Rs 176.30 after the Central Bureau of
Investigation (CBI) began a probe under the Prevention of Corruption Act, 1988
against 59 current account holders of Bank of Baroda and unknown officials of the
state-run bank and some private persons. The allegation is that the current account
holders of the bank and bank officials conspired to send overseas remittances of
foreign exchange worth approximately Rs 6000 crore in illegal and irregular manner
in violation of established banking norms under the garb of payments towards
suspected non-existent imports. The CBI began investigation into the case after a
complaint from Bank of Baroda.
In overseas stock markets, European stocks edged lower, taking a breather from a
solid rally last week. Chinese stocks led gains in Asian markets on stimulus
measures from China and signals of reform in China's telecommunications sector. In
mainland China, the Shanghai Composite ended with gains of 3.28%. China's central
bank announced over the weekend that it will expand a relending trial to nine more
cities and provinces, including Shanghai and Beijing. The plan, currently in place in
Shandong and Guangdong, allows banks to pledge certain assets to secure loans
from the central bank.
OPTION STRATEGY
In todays session we have seen call buying in 8100 and 8200 strike price, we may see 8200 as a
strong resistance level in coming days.
RELIANCE 900 and 920 calls and puts were so active, we may see buying above 900 level.
INFOSIS 1160 puts were so active today, we may see more selling below 1160.
STOCKS TO WATCH
www.capitalstars.com | CapitalStars Research
MARUTI:
SELL MARUTI AS REMAIN BELOW 4300 WE MAY SEE 4200/4100 IN COMING DAYS.
ONGC:
Buy ONGC above 250 level we may see 270/280, below 250 major support will be
242.
AMBUJA CEM:
Sell AMBUJA as remain below 215 we may see 205/195 level in coming days.
DISCLAIMER
The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the
right to choose the product/s that suits them the most.
Use of this report in no way constitutes a client/advisor relationship, all information we communicate to
you (the subscriber) either through our Web site or other forms of communications, are purely for
informational purposes only.
We recommend seeking individual investment advice before making any investment, for you are
assuming sole liability for your investments. Capital Stars will in no way have discretionary authority
over your trading or investment accounts.
All rights reserved.